| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/500-1/5000 | Human,Mouse,Rat |
| Aliases | BCL1, PRAD1, U21B31, D11S287E |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human CCND1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇涉及CCND1(Cyclin D1)抗体应用的参考文献摘要：
1. **"Cyclin D1 in breast cancer: a molecular marker for patient prognosis"**
*Authors: Gillett C, et al.*
**摘要**：本研究通过免疫组化(使用兔源CCND1单克隆抗体)分析乳腺癌组织中Cyclin D1蛋白表达，发现其过表达与患者预后不良相关，提示CCND1可作为乳腺癌的潜在生物标志物。
2. **"Immunohistochemical detection of Cyclin D1 in paraffin-embedded tissue sections: a comparison of antibody performance"**
*Authors: Sáez A, et al.*
**摘要**：比较了5种商用CCND1抗体在石蜡包埋组织中的检测效果，发现克隆号SP4和DCS-6抗体特异性最佳，为临床病理诊断中抗体选择提供了实验依据。
3. **"Targeting Cyclin D1 in mantle cell lymphoma: mechanisms of resistance to CDK4/6 inhibition"**
*Authors: Chiron D, et al.*
**摘要**：利用Western blot(CCND1抗体：Cell Signaling Technology #2926)和基因沉默技术，揭示套细胞淋巴瘤中CCND1信号通路异常激活导致CDK4/6抑制剂耐药的新机制。
注：实际文献需通过PubMed等数据库验证，以上为基于典型研究的模拟示例。
The CCND1 antibody is a crucial tool in molecular and clinical research, targeting cyclin D1—a protein encoded by the CCND1 gene (also known as BCL1 or PRAD1). Cyclin D1 plays a central role in regulating the cell cycle, particularly during the G1-to-S phase transition, by forming complexes with cyclin-dependent kinases (CDKs) like CDK4/6. These complexes phosphorylate retinoblastoma (Rb) proteins, promoting cell cycle progression. Dysregulation of CCND1. often due to gene amplification or chromosomal translocations, is implicated in various cancers, including breast cancer, mantle cell lymphoma, and squamous cell carcinomas.
CCND1 antibodies are widely utilized in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect cyclin D1 overexpression in tumor tissues. Their specificity helps distinguish malignancies associated with CCND1 abnormalities, aiding in diagnosis and prognosis. For example, cyclin D1 overexpression is a hallmark of mantle cell lymphoma, where it serves as a diagnostic biomarker. Additionally, these antibodies support functional studies exploring CCND1's role in oncogenesis, therapeutic resistance, and interactions with signaling pathways like Wnt/β-catenin or PI3K/AKT.
Researchers must validate CCND1 antibodies rigorously, as isoforms and post-translational modifications can affect detection accuracy. Their application extends to preclinical studies targeting cyclin D1-CDK complexes for cancer therapy, highlighting both diagnostic and therapeutic relevance.
×
